VC-backed Biotechnology Firms: What is Entrepreneurs’ Return?

Authors

DOI:

https://doi.org/10.5912/jcb722

Abstract

Valuation is a highly significant process used extensively not only by start-ups seeking Venture Capital (VC) funding but also by large, established companies that are in need to set a price for an acquisition or merger. Such process becomes increasingly complex in the biotechnology sector where the realization of the true value of a firm is largely correlated with the success or failure of lead drug candidates undergoing clinical trials. In this article, the author sets up a simple long-term financial model that aims at providing an easy tool for estimating entrepreneurs’ return at exit.

Author Biography

Demetris Iacovides, GENESIS Pharma S.A.

Corporate Development Manager

References

Bogdan, B., and Villiger, R. (2008) Valuation in Life Sciences. Springer Berlin Heidelberg.

MorningStar (2011) Risk Premia Over Time Report

Driessen, J., Lin, T., and Phalippou L. (2012) A New Method to Estimate Risk and Return of Non-traded Assets from Cash Flows: The Case of Private Equity Funds. Journal of Financial and Quantitative Analysis 47(03): 511-535.

Damodaran (2015) Betas by Sector (US) http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/Betas.html

DiMasi, J. A., Feldman, L., Seckler, A., and Wilson, A. (2010) Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology & Therapeutics 87(3): 272-277.

Damodaran (2015) Cost of Capital by Sector (US) http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/wacc.htm

Damodaran (2015) Margins by Sector (US) http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/margin.html

EvaluatePharma Database – Average values for companies with sales between $10 and $100 mn.

Published

2016-05-05

Issue

Section

Article